Encryption systems rely on “random” numbers, but conventional computers can’t generate them perfectly. New research shows that quantum physics can. By Alexander Nazaryan Researchers in Switzerland ...

The tech giant says a breakthrough in data center networking has dramatically accelerated the flow of information through its massive cloud infrastructure. The new technology hinges on a “quasi-random ...

Neighbors of Port Washington's $15 billion AI data center and advocacy groups are voicing public health and environmental concerns about plans for backup diesel generators at the site under review by ...

The vast data centers that power artificial intelligence guzzle huge amounts of energy but they also have another alarming impact, according to new research. They are creating “heat islands,” warming ...

The mammoth Project Jupiter data centers complex being constructed for Oracle Corp., in the Santa Teresa, New Mexico area, on El Paso's west edge, is to generate more power than El Paso Electric’s ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...

Atlas Compute has proposed a dual data center and power plant in St. Lucie County. The data center is planned to be running by 2027. Atlas Compute, however, has yet to apply for any county approvals.

Add Futurism (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. Now ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...